← Leaderboards
Giedre Krenciute
St. Jude Children'S Research Hospital
$4,894,202
Attributed
$6,262,753
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,262,753 · 3
By mechanism
R01$4,209,927 · 2
U01$2,052,826 · 1
Top collaborators
- Stephen C Mack3 shared
- Timothy N Phoenix3 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Suzanne J Baker$15,879,154
- Stephen C Mack$5,806,636
- Christopher C. Derenzo$1,462,442
- Linda M Hendershot$7,381,128
- Jeremy Joseph Porter Shaw$145,676
Others in their field
Other Emerging Leaders on “Mouse Model”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$13,186,126
- Nuno Macarico Da Costa · Allen Institute$11,726,937
- Forrest Christie Collman · Allen Institute$11,726,937
- Jacqueline K White · Jackson Laboratory$11,670,339
- Thomas Dick · Rbhs-New Jersey Medical School$11,611,284
Research focus
Mouse ModelFrequenciesCell TherapyCell PhysiologyExhaustionImmune ResponseImmuneMolecularT-LymphocyteTumorCellsChildhood Brain NeoplasmEffector T CellBrain NeoplasmsCancer CellClinical ResearchChimeric Antigen Receptor T CellsImmunocompetentChimeric Antigen ReceptorImmunotherapyEngineered T CellsAntitumor ResponseCd276 GeneCytokine
Grant awards (12)
GENETICALLY ENGINEERED T CELLS FOR DIPG$503,626
R01 · FY2025 · NS · contact PI
Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma$498,337
U01 · FY2025 · CA
Improving genetically engineered T cells for medulloblastomas$444,775
R01 · FY2025 · NS · contact PI
Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma$746,809
U01 · FY2024 · CA
GENETICALLY ENGINEERED T CELLS FOR DIPG$488,517
R01 · FY2024 · NS · contact PI
Improving genetically engineered T cells for medulloblastomas$431,432
R01 · FY2024 · NS · contact PI
Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma$807,680
U01 · FY2023 · CA
GENETICALLY ENGINEERED T CELLS FOR DIPG$503,626
R01 · FY2023 · NS · contact PI
Improving genetically engineered T cells for medulloblastomas$444,775
R01 · FY2023 · NS · contact PI
GENETICALLY ENGINEERED T CELLS FOR DIPG$503,626
R01 · FY2022 · NS · contact PI
Improving genetically engineered T cells for medulloblastomas$444,775
R01 · FY2022 · NS · contact PI
Improving genetically engineered T cells for medulloblastomas$444,775
R01 · FY2021 · NS · contact PI